Better characterization of vinflunine pharmacokinetics variability and exposure/toxicity relationship to improve its use: Analyses from 18 trials.
Fiche publication
Date publication
mai 2018
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr SCHMITT Antonin
Tous les auteurs :
Schmitt A, Nguyen L, Zorza G, Ferré P, Pétain A
Lien Pubmed
Résumé
Vinflunine is a novel tubulin-targeted inhibitor indicated as a single agent for the treatment of bladder cancers after failure of prior platinum-based therapy. Its pharmacokinetics (PK) and pharmacodynamics (PD) have been independently characterized through several phase I and phase II studies. However, no global pharmacometric analysis had been conducted as yet.
Mots clés
PK/PD, modelling, pharmacokinetics, vinflunine
Référence
Br J Clin Pharmacol. 2018 05;84(5):900-910